Reader sentiment, not investment advice. One vote per visitor; click again to change it.
MAZE last changed hands at $26.43 (flat). At $1.47B, Maze Therapeutics is ranked #2986 by size among the 3132 stocks on BeStock.
Over the past 52 weeks it has traded between $21.95 and $53.65, so it sits 50.7% below the top of that range.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
MAZE is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$26.43 is the latest print for MAZE, a move of +0.00% against yesterday's close of $26.43. Today's low and high so far: $25.78 and $27.03.
Equity value comes to $1.47B at the current price. By that measure it is number 2986 of the 3132 names in our coverage.
The year's floor is $21.95 and the ceiling $53.65. Shares are 50.7% away from that ceiling.
Our data shows no dividend paid by Maze Therapeutics over the trailing twelve months.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on MAZE.